首页 > 市场调查报告书 > 製药

血浆蛋白分解酵素C1抑制剂治疗的全球市场:各药物类型，各剂量，各流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

市场调查报告书

商品编码

1085743

血浆蛋白分解酵素C1抑制剂治疗的全球市场:各药物类型，各剂量，各流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日期: 2022年05月13日 | 出版商:

Coherent Market Insights | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在遗传性血管水肿(HAE)治疗中使用血浆来源的C1酯酶阻碍产品的倾向日益增加，牵引全球血浆蛋白分解酵素C1抑制剂治疗市场成长。

本报告提供全球血浆蛋白分解酵素C1抑制剂治疗市场相关调查分析，推动市场要素与阻碍因素，市场机会，COVID-19影响，各药物类型、剂量、流通管道、地区的市场分析，竞争情形等资讯。

企业简介
- CSL Behring LLC.
- 临床试验阶段的组合
- Takeda Pharmaceutical Company Limited
- 临床试验阶段的组合
- Ionis Pharmaceuticals, Inc.
- 临床试验阶段的组合
- Pharming Technologies B.V.
- 临床试验阶段的组合
- Centogene AG
- 临床试验阶段的组合
- BioCryst Pharmaceuticals
- 临床试验阶段的组合
- KalVista Pharmaceuticals, Inc.
- 临床试验阶段的组合

简介目录

Product Code: CMI4262

C1-inhibitor (C1-H) belongs to the superfamily of serine protease inhibitors. C1-inhibitors controls the activation of the C1 complex. It forms a proteolytically inactive stoichiometric complex with the C1r or C1s proteases. It also plays an important role in regulating important physiological pathways including complement activation, blood coagulation, fibrinolysis, and generation of kinins. It is the most efficient inhibitor of FXIIa factors and also inhibits chymotrypsin and kallikrein.

Market Dynamics

Hereditary angioedema (HAE) is the disease condition characterized by the C1 esterase inhibitor deficiency. According to reported data by National Center for Biotechnology Information in 2013, the estimated prevalence of HAE in the general population is between 1 in 10,000 and 1 in 150,000 individuals worldwide. Cinryze, a pharmaceutical-grade C1-inhibitor, was approved by U.S.FDA for the treatment of HAE in 2008. Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product; it has been approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. Thus, the increasing trend of using plasma-derived C1 esterase inhibitor products in HAE treatment is expected to drive growth of the global plasma protease C1-inhibitor treatment market.

Key features of the study:

This report provides in-depth analysis of the global plasma protease C1-inhibitor treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global plasma protease C1-inhibitor treatment market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics

The global plasma protease C1-inhibitor treatment market report caters to various stakeholders in this industry including investors, suppliers, drugs manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma protease C1-inhibitor treatment market.

Detailed Segmentation:

Global Plasma Protease C1-inhibitor Treatment Market, By Drug Type:
- C1-inhibitors
- Kallikrein Inhibitor
- Selective Bradykinin B2 Receptor Antagonist
Global Plasma Protease C1-inhibitor Treatment Market, By Dosage:
- Lyophilized
- Injectable
Global Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Plasma Protease C1-inhibitor Treatment Market, By Region:
- North America
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - U.S.
  - Canada
- Latin America
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
- Europe
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
- Asia Pacific
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country:
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - GCC
  - Israel
  - Rest of Middle East
- Africa
  - By Drug Type:
  - C1-inhibitors
  - Kallikrein Inhibitor
  - Selective Bradykinin B2 Receptor Antagonist
  - By Dosage:
  - Lyophilized
  - Injectable
  - By Distribution Channel:
  - Hospital Pharmacies
  - Retail Pharmacies
  - Online Pharmacies
  - By Country/Region:
  - South Africa
  - Central Africa
  - North Africa
Company Profiles:
- CSL Behring LLC *
  - Company Overview
  - Clinical Trial Phase Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Takeda Pharmaceutical Company Limited
- Ionis Pharmaceuticals, Inc.
- Pharming Technologies B.V.
- Centogene AG
- BioCryst Pharmaceuticals
- KalVista Pharmaceuticals, Inc.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
Market Definition and Scope
Executive Summary
Market Snippet, By Drug Type
Market Snippet, By Dosage
Market Snippet, By Distribution Channel
Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Drivers
Restraints
Impact Analysis
Market Opportunities
Collaboration and acquisition

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

Post COVID-19 Impact
COVID-19 Impact on Research and Development Activities
Demand and Supply Analysis
Overall impact on manufacturing industry

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- C1-inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Kallikrein Inhibitor
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Selective Bradykinin B2 Receptor Antagonist
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- Lyophilized
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Injectable
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, 2022 and 2028 (%)
Y-o-Y Growth Analysis, 2017 - 2028
Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

Introduction
Market Share Analysis, By Country, 2022 and 2028 (%)
Y-o-Y Growth Analysis, For Countries, 2017 - 2028
North America
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- U.S.
- Canada
Latin America
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country, 2017 - 2028 (US$ Mn)
- GCC
- Israel
- Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Drug Type, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Dosage, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Distribution Channel, 2017 - 2028 (US$ Mn)
Market Size and Forecast, By Country/Region, 2017 - 2028 (US$ Mn)
- South Africa
- Central Africa
- North Africa

9. Competitive Landscape

Company Profiles
CSL Behring LLC.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Takeda Pharmaceutical Company Limited
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Ionis Pharmaceuticals, Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Pharming Technologies B.V.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
Centogene AG
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
BioCryst Pharmaceuticals
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies
KalVista Pharmaceuticals, Inc.
Company Overview
Clinical Trial Phase Portfolio
Financial Overview
Key Highlights
Market Strategies

Browse 32 market data tables and 30 figures on " Plasma Protease C1-inhibitor Treatment Market - Global forecast to 2028".

02-2729-4219

+886-2-2729-4219

License/价格

FAQ

血浆蛋白分解酵素C1抑制剂治疗的全球市场:各药物类型，各剂量，各流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章调查目的、前提条件

第2章市场范围

第3章市场动态、法规、趋势分析

第4章血浆蛋白分解酵素C1抑制剂治疗市场:COVID-19流行的影响

第5章血浆蛋白分解酵素C1抑制剂治疗市场:各药物类型(2017年～2028年)

第6章血浆蛋白分解酵素C1抑制剂治疗市场:各剂量(2017年～2028年)

第7章血浆蛋白分解酵素C1抑制剂治疗市场:各流通管道(2017年～2028年)

第8章血浆蛋白分解酵素C1抑制剂治疗市场:各地区(2017年～2028年)

第9章竞争情形

Market Dynamics

Key features of the study:

Detailed Segmentation:

"" marked represents similar segmentation in other categories in the respective section.*

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

9. Competitive Landscape

血浆蛋白分解酵素C1抑制剂治疗的全球市场:各药物类型，各剂量，各流通管道，各地区 - 规模，占有率，展望，机会分析(2022年～2028年)

Plasma Protease C1-inhibitor Treatment Market, by Drug Type, by Dosage, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目录

第1章 调查目的、前提条件

第2章 市场范围

第3章 市场动态、法规、趋势分析

第4章 血浆蛋白分解酵素C1抑制剂治疗市场:COVID-19流行的影响

第5章 血浆蛋白分解酵素C1抑制剂治疗市场:各药物类型(2017年～2028年)

第6章 血浆蛋白分解酵素C1抑制剂治疗市场:各剂量(2017年～2028年)

第7章 血浆蛋白分解酵素C1抑制剂治疗市场:各流通管道(2017年～2028年)

第8章 血浆蛋白分解酵素C1抑制剂治疗市场:各地区(2017年～2028年)

第9章 竞争情形

Market Dynamics

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Plasma Protease C1-inhibitor Treatment Market - Impact of COVID-19 Pandemic

5. Plasma Protease C1-inhibitor Treatment Market, By Drug Type, 2017 - 2028 (US$ Mn)

6. Plasma Protease C1-inhibitor Treatment Market, By Dosage, 2017 - 2028 (US$ Mn)

7. Plasma Protease C1-inhibitor Treatment Market, By Distribution Channel, 2017 - 2028 (US$ Mn)

8. Plasma Protease C1-inhibitor Treatment Market, By Region, 2017 - 2028 (US$ Mn)

9. Competitive Landscape

第1章调查目的、前提条件

第2章市场范围

第3章市场动态、法规、趋势分析

第4章血浆蛋白分解酵素C1抑制剂治疗市场:COVID-19流行的影响

第5章血浆蛋白分解酵素C1抑制剂治疗市场:各药物类型(2017年～2028年)

第6章血浆蛋白分解酵素C1抑制剂治疗市场:各剂量(2017年～2028年)

第7章血浆蛋白分解酵素C1抑制剂治疗市场:各流通管道(2017年～2028年)

第8章血浆蛋白分解酵素C1抑制剂治疗市场:各地区(2017年～2028年)

第9章竞争情形

"" marked represents similar segmentation in other categories in the respective section.*